Reportedly, Merck & Co., Inc. (MRK) has partnered with five Indian generic drugmakers, including Sun Pharmaceutical Industries Ltd & Cipla Ltd, to expand production and access to its experimental COVID-19 drug, molnupiravir.
The partnership will allow the companies with licenses to supply Merck’s molnupiravir to India and more than 100 low- and middle-income countries after approvals for emergency authorization by local regulatory agencies, are attained, informed Merck. The move is also an initiative to address the COVID-19 crisis in India, which is reporting alarming cases and deaths every day.
Merck’s non-exclusive production pacts for molnupiravir are with companies including Dr.Reddy’s Laboratories Ltd and privately held companies Emcure Pharmaceuticals Ltd and Hetero Labs Ltd.
Molnupiravir is an antiviral therapy for the treatment of non-hospitalized COVID-19 patients, which Merck is developing with Ridgeback Biotherapeutics.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.